Topic
NAD+ and its precursors, rapamycin, metformin, the mitochondrial peptides and the senolytics — the compounds taken for a result that is measured in decades.
The defining problem of this category is that the outcome is unobservable on any timescale you can track. What you can track are the markers people use as proxies: fasting glucose and HbA1c, lipids, ApoB, hsCRP, and the biomarker panels that feed a biological-age estimate. Those move on a scale of months, which makes a consistent lab cadence more valuable here than anywhere else in the library.
The metabolic panel most of this category is aimed at: fasting glucose, HbA1c, a full lipid panel with ApoB, and hsCRP. Repeat them on a fixed interval rather than when you feel like it, because the interval is what makes the trend readable.
A model that maps a set of lab markers plus your chronological age onto an estimated physiological one. BioHack Track uses two: Levine PhenoAge where your draw carries its nine markers, and Klemera-Doubal where it does not, so an incomplete panel still gives you a number. Every result names the method that produced it and any marker it estimated rather than measured, and below five usable markers it declines rather than guessing. These are research models, not a diagnosis.
Essentially none of them. Several — metformin, rapamycin — are approved medicines for entirely different indications, and their use here is off-label. The compound pages distinguish the two cases explicitly.
Every figure on these pages is sourced the same way — see the editorial policy for the hierarchy, and the full library for all 208 compounds.